The Ratio of Plasma Amyloid-β 1-42 over Serum Albumin Can Be a Novel Biomarker Signature for Diagnosing End-Stage Renal Disease-Associated Cognitive Impairment
Journal
Journal of Alzheimer's Disease
Journal Volume
97
Journal Issue
3
Pages
1393-1405
Date Issued
2024
Author(s)
Abstract
Cognitive impairment (CI) is one of the major complications in chronic kidney disease patients, especially those with end-stage renal disease (ESRD). Limited biomarkers have been found that can significantly predict ESRD-associated cognitive decline.
Subjects
Albumin; Alzheimer’s disease; amyloid-beta 1-42; biomarker signature; cognitive impairment; end-stage renal disease
Publisher
IOS Press BV
Type
journal article